A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Location: Kinevant Study Site
Conditions: Kinevant Study Site
Palo Alto, California
Iowa City, Iowa
Kansas City, Kansas
New Orleans, Louisiana
Greenville, North Carolina
Charleston, South Carolina
Rock Hill, South Carolina
Falls Church, Virginia
This is a randomized, double-blind, placebo-controlled study with an OLE.
Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
All participants, who complete the 26-week Double-blind Treatment Period, may be eligible to participate in the 28-week OLE.
Further details are in the protocol.